{"friendlyName": "Fetch Stage - Nerd", "mainSection": {"title": "Prostate cancer", "sectionItems": [{"text": "Prostate cancer is cancer of the prostate. Prostate cancer is the second most common cancerous tumor worldwide and is the fifth leading cause of cancer-related mortality among men. The prostate is a gland in the male reproductive system that surrounds the urethra just below the bladder. It is located in the hypogastric region of the abdomen. To give an idea of where it is located, the bladder is superior to the prostate gland as shown in the image The rectum is posterior in perspective to the prostate gland and the ischial tuberosity of the pelvic bone is inferior. Only those who have male reproductive organs are able to get prostate cancer.  Most prostate cancers are slow growing. Cancerous cells may spread to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, symptoms include pain or difficulty urinating, blood in the urine, or pain in the pelvis or back. Benign prostatic hyperplasia may produce similar symptoms. Other late symptoms include fatigue, due to low levels of red blood cells.", "annotations": [{"surface": "Prostate cancer", "start": 0, "end": 15, "uri": "https://calvoritmo.com/tfm/entity/2657c876-c7c8-45b2-838a-6f355b89ad3c", "source": "b"}, {"surface": "cancer", "start": 19, "end": 25, "uri": "http://dbpedia.org/resource/Cancer", "source": "a"}, {"surface": "prostate", "start": 33, "end": 41, "uri": "http://dbpedia.org/resource/Prostate", "source": "a"}, {"surface": "gland", "start": 199, "end": 204, "uri": "http://dbpedia.org/resource/Gland", "source": "a"}, {"surface": "male reproductive system", "start": 212, "end": 236, "uri": "http://dbpedia.org/resource/Male_reproductive_system", "source": "a"}, {"surface": "urethra", "start": 256, "end": 263, "uri": "http://dbpedia.org/resource/Urethra", "source": "a"}, {"surface": "bladder", "start": 279, "end": 286, "uri": "http://dbpedia.org/resource/Bladder", "source": "a"}, {"surface": "spread", "start": 711, "end": 717, "uri": "http://dbpedia.org/resource/Metastasis", "source": "a"}, {"surface": "bones", "start": 763, "end": 768, "uri": "http://dbpedia.org/resource/Bone", "source": "a"}, {"surface": "lymph nodes", "start": 773, "end": 784, "uri": "http://dbpedia.org/resource/Lymph_node", "source": "a"}, {"surface": "urinating", "start": 875, "end": 884, "uri": "http://dbpedia.org/resource/Urination", "source": "a"}, {"surface": "blood in the urine", "start": 886, "end": 904, "uri": "http://dbpedia.org/resource/Hematuria", "source": "a"}, {"surface": "pain in the pelvis", "start": 909, "end": 927, "uri": "http://dbpedia.org/resource/Pelvic_pain", "source": "a"}, {"surface": "Benign prostatic hyperplasia", "start": 937, "end": 965, "uri": "http://dbpedia.org/resource/Benign_prostatic_hyperplasia", "source": "a"}, {"surface": "low levels of red blood cells", "start": 1040, "end": 1069, "uri": "http://dbpedia.org/resource/Anemia", "source": "a"}, {"surface": "Prostate cancer", "start": 0, "end": 15, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "cancer", "start": 19, "end": 25, "uri": "http://dbpedia.org/resource/Cancer", "source": "dbpedia_spotlight"}, {"surface": "prostate", "start": 33, "end": 41, "uri": "http://dbpedia.org/resource/Prostate", "source": "dbpedia_spotlight"}, {"surface": "Prostate cancer", "start": 43, "end": 58, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "tumor", "start": 95, "end": 100, "uri": "http://dbpedia.org/resource/Neoplasm", "source": "dbpedia_spotlight"}, {"surface": "mortality", "start": 160, "end": 169, "uri": "http://dbpedia.org/resource/Infant", "source": "dbpedia_spotlight"}, {"surface": "prostate", "start": 185, "end": 193, "uri": "http://dbpedia.org/resource/Prostate", "source": "dbpedia_spotlight"}, {"surface": "male reproductive system", "start": 212, "end": 236, "uri": "http://dbpedia.org/resource/Male_reproductive_system", "source": "dbpedia_spotlight"}, {"surface": "urethra", "start": 256, "end": 263, "uri": "http://dbpedia.org/resource/Urethra", "source": "dbpedia_spotlight"}, {"surface": "bladder", "start": 279, "end": 286, "uri": "http://dbpedia.org/resource/Urinary_bladder", "source": "dbpedia_spotlight"}, {"surface": "abdomen", "start": 335, "end": 342, "uri": "http://dbpedia.org/resource/Abdomen", "source": "dbpedia_spotlight"}, {"surface": "bladder", "start": 388, "end": 395, "uri": "http://dbpedia.org/resource/Urinary_bladder", "source": "dbpedia_spotlight"}, {"surface": "prostate gland", "start": 415, "end": 429, "uri": "http://dbpedia.org/resource/Prostate", "source": "dbpedia_spotlight"}, {"surface": "rectum", "start": 456, "end": 462, "uri": "http://dbpedia.org/resource/Rectum", "source": "dbpedia_spotlight"}, {"surface": "prostate gland", "start": 498, "end": 512, "uri": "http://dbpedia.org/resource/Prostate", "source": "dbpedia_spotlight"}, {"surface": "ischial tuberosity", "start": 521, "end": 539, "uri": "http://dbpedia.org/resource/Ischial_tuberosity", "source": "dbpedia_spotlight"}, {"surface": "pelvic bone", "start": 547, "end": 558, "uri": "http://dbpedia.org/resource/Hip_bone", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 633, "end": 648, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "prostate", "start": 656, "end": 664, "uri": "http://dbpedia.org/resource/Prostate", "source": "dbpedia_spotlight"}, {"surface": "lymph nodes", "start": 773, "end": 784, "uri": "http://dbpedia.org/resource/Lymph_node", "source": "dbpedia_spotlight"}, {"surface": "pain", "start": 856, "end": 860, "uri": "http://dbpedia.org/resource/Pain", "source": "dbpedia_spotlight"}, {"surface": "urine", "start": 899, "end": 904, "uri": "http://dbpedia.org/resource/Urination", "source": "dbpedia_spotlight"}, {"surface": "pain", "start": 909, "end": 913, "uri": "http://dbpedia.org/resource/Pain", "source": "dbpedia_spotlight"}, {"surface": "pelvis", "start": 921, "end": 927, "uri": "http://dbpedia.org/resource/Pelvis", "source": "dbpedia_spotlight"}, {"surface": "Benign prostatic hyperplasia", "start": 937, "end": 965, "uri": "http://dbpedia.org/resource/Benign_prostatic_hyperplasia", "source": "dbpedia_spotlight"}, {"surface": "fatigue", "start": 1024, "end": 1031, "uri": "http://dbpedia.org/resource/Fatigue", "source": "dbpedia_spotlight"}, {"surface": "red blood cells", "start": 1054, "end": 1069, "uri": "http://dbpedia.org/resource/Anemia", "source": "dbpedia_spotlight"}, {"surface": "second", "start": 66, "end": 72, "uri": "https://calvoritmo.com/tfm/entity/adda0ce4-e8a3-4094-96d3-4c85a62c4517", "source": "spacy"}, {"surface": "fifth", "start": 122, "end": 127, "uri": "https://calvoritmo.com/tfm/entity/cd31f6ea-63e4-4a70-a091-0c24d4429085", "source": "spacy"}]}, {"text": "Factors that increase the risk of prostate cancer include older age, family history and race. About 99% of cases occur after age 50. A first-degree relative with the disease increases the risk two- to three-fold. Other factors include a diet high in processed meat and red meat, while the risk from a high intake of milk products is inconclusive. An association with gonorrhea has been found, although no reason for this relationship has been identified. An increased risk is associated with the BRCA mutations. Diagnosis is by biopsy. Medical imaging may be done to assess whether metastasis is present.", "annotations": [{"surface": "race", "start": 88, "end": 92, "uri": "http://dbpedia.org/resource/Race_(human_classification)", "source": "a"}, {"surface": "first-degree relative", "start": 135, "end": 156, "uri": "http://dbpedia.org/resource/First-degree_relative", "source": "a"}, {"surface": "diet", "start": 237, "end": 241, "uri": "http://dbpedia.org/resource/Diet_(nutrition)", "source": "a"}, {"surface": "processed meat", "start": 250, "end": 264, "uri": "http://dbpedia.org/resource/Processed_meat", "source": "a"}, {"surface": "red meat", "start": 269, "end": 277, "uri": "http://dbpedia.org/resource/Red_meat", "source": "a"}, {"surface": "milk products", "start": 316, "end": 329, "uri": "http://dbpedia.org/resource/Milk_products", "source": "a"}, {"surface": "gonorrhea", "start": 367, "end": 376, "uri": "http://dbpedia.org/resource/Gonorrhea", "source": "a"}, {"surface": "BRCA mutations", "start": 496, "end": 510, "uri": "http://dbpedia.org/resource/BRCA_mutation", "source": "a"}, {"surface": "biopsy", "start": 528, "end": 534, "uri": "http://dbpedia.org/resource/Biopsy", "source": "a"}, {"surface": "Medical imaging", "start": 536, "end": 551, "uri": "http://dbpedia.org/resource/Medical_imaging", "source": "a"}, {"surface": "metastasis", "start": 582, "end": 592, "uri": "http://dbpedia.org/resource/Metastasis", "source": "a"}, {"surface": "prostate cancer", "start": 34, "end": 49, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "first-degree relative", "start": 135, "end": 156, "uri": "http://dbpedia.org/resource/First-degree_relatives", "source": "dbpedia_spotlight"}, {"surface": "processed meat", "start": 250, "end": 264, "uri": "http://dbpedia.org/resource/Processed_meat", "source": "dbpedia_spotlight"}, {"surface": "red meat", "start": 269, "end": 277, "uri": "http://dbpedia.org/resource/Red_meat", "source": "dbpedia_spotlight"}, {"surface": "milk", "start": 316, "end": 320, "uri": "http://dbpedia.org/resource/Milk", "source": "dbpedia_spotlight"}, {"surface": "gonorrhea", "start": 367, "end": 376, "uri": "http://dbpedia.org/resource/Gonorrhea", "source": "dbpedia_spotlight"}, {"surface": "BRCA mutations", "start": 496, "end": 510, "uri": "http://dbpedia.org/resource/BRCA_mutation", "source": "dbpedia_spotlight"}, {"surface": "biopsy", "start": 528, "end": 534, "uri": "http://dbpedia.org/resource/Biopsy", "source": "dbpedia_spotlight"}, {"surface": "Medical imaging", "start": 536, "end": 551, "uri": "http://dbpedia.org/resource/Medical_imaging", "source": "dbpedia_spotlight"}, {"surface": "metastasis", "start": 582, "end": 592, "uri": "http://dbpedia.org/resource/Metastasis", "source": "dbpedia_spotlight"}, {"surface": "About 99%", "start": 94, "end": 103, "uri": "https://calvoritmo.com/tfm/entity/602e1aa1-0946-4584-9c25-5edb00d760e2", "source": "spacy"}, {"surface": "age 50", "start": 125, "end": 131, "uri": "https://calvoritmo.com/tfm/entity/dd3b7b63-a386-4d87-8814-4f0e58a8cdaa", "source": "spacy"}, {"surface": "first", "start": 135, "end": 140, "uri": "https://calvoritmo.com/tfm/entity/99392afd-6a33-4701-8d72-931b167deefd", "source": "spacy"}, {"surface": "three-fold", "start": 201, "end": 211, "uri": "https://calvoritmo.com/tfm/entity/db69718d-53de-4f4b-9816-fc4b910ff741", "source": "spacy"}]}, {"text": "Prostate cancer screening, including prostate-specific antigen (PSA) testing, increases cancer detection but whether it improves outcomes is controversial. Informed decision making is recommended for those 55 to 69 years old. Testing, if carried out, is more appropriate for those with a longer life expectancy. Although 5\u03b1-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk, and are not recommended for prevention. Vitamin or mineral supplementation does not appear to affect risk.", "annotations": [{"surface": "Prostate cancer screening", "start": 0, "end": 25, "uri": "http://dbpedia.org/resource/Prostate_cancer_screening", "source": "a"}, {"surface": "prostate-specific antigen", "start": 37, "end": 62, "uri": "http://dbpedia.org/resource/Prostate-specific_antigen", "source": "a"}, {"surface": "5\u03b1-reductase inhibitors", "start": 321, "end": 344, "uri": "http://dbpedia.org/resource/5\u03b1-reductase_inhibitors", "source": "a"}, {"surface": "Vitamin", "start": 470, "end": 477, "uri": "http://dbpedia.org/resource/Vitamin", "source": "a"}, {"surface": "mineral", "start": 481, "end": 488, "uri": "http://dbpedia.org/resource/Dietary_element", "source": "a"}, {"surface": "Prostate cancer screening", "start": 0, "end": 25, "uri": "http://dbpedia.org/resource/Prostate_cancer_screening", "source": "dbpedia_spotlight"}, {"surface": "prostate-specific antigen", "start": 37, "end": 62, "uri": "http://dbpedia.org/resource/Prostate-specific_antigen", "source": "dbpedia_spotlight"}, {"surface": "PSA", "start": 64, "end": 67, "uri": "http://dbpedia.org/resource/Prostate-specific_antigen", "source": "dbpedia_spotlight"}, {"surface": "cancer", "start": 88, "end": 94, "uri": "http://dbpedia.org/resource/Cancer", "source": "dbpedia_spotlight"}, {"surface": "Informed decision", "start": 156, "end": 173, "uri": "http://dbpedia.org/resource/Informed_Decision", "source": "dbpedia_spotlight"}, {"surface": "life expectancy", "start": 295, "end": 310, "uri": "http://dbpedia.org/resource/Life_expectancy", "source": "dbpedia_spotlight"}, {"surface": "5\u03b1-reductase", "start": 321, "end": 333, "uri": "http://dbpedia.org/resource/5\u03b1-Reductase", "source": "dbpedia_spotlight"}, {"surface": "cancer", "start": 374, "end": 380, "uri": "http://dbpedia.org/resource/Cancer", "source": "dbpedia_spotlight"}, {"surface": "cancer", "start": 417, "end": 423, "uri": "http://dbpedia.org/resource/Cancer", "source": "dbpedia_spotlight"}, {"surface": "mineral", "start": 481, "end": 488, "uri": "http://dbpedia.org/resource/Mineral", "source": "dbpedia_spotlight"}, {"surface": "PSA", "start": 64, "end": 67, "uri": "https://calvoritmo.com/tfm/entity/f29968f5-c5e8-4caa-9c7d-22e2f08629e1", "source": "spacy"}, {"surface": "55 to 69 years old", "start": 206, "end": 224, "uri": "https://calvoritmo.com/tfm/entity/08497a2f-7289-4a69-840b-11399d27ed79", "source": "spacy"}, {"surface": "5\u03b1", "start": 321, "end": 323, "uri": "https://calvoritmo.com/tfm/entity/4f7e0647-feb2-41fa-b3ff-616ffe609f14", "source": "spacy"}, {"surface": "Vitamin", "start": 470, "end": 477, "uri": "https://calvoritmo.com/tfm/entity/7f58c351-5f20-41d6-a7c9-576cf11ceaaf", "source": "spacy"}]}, {"text": "Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy, or chemotherapy. Tumors limited to the prostate may be curable. Pain medications, bisphosphonates, and targeted therapy, among others, may be useful. Outcomes depend on age, health status and how aggressive and extensive the cancer is. Most men with prostate cancer do not die from it. The United States five-year survival rate is 98%.", "annotations": [{"surface": "active surveillance", "start": 28, "end": 47, "uri": "http://dbpedia.org/resource/Active_surveillance_of_prostate_cancer", "source": "a"}, {"surface": "watchful waiting", "start": 51, "end": 67, "uri": "http://dbpedia.org/resource/Watchful_waiting", "source": "a"}, {"surface": "surgery", "start": 115, "end": 122, "uri": "http://dbpedia.org/resource/Radical_prostatectomy", "source": "a"}, {"surface": "radiation therapy", "start": 124, "end": 141, "uri": "http://dbpedia.org/resource/Radiation_therapy", "source": "a"}, {"surface": "hormone therapy", "start": 143, "end": 158, "uri": "http://dbpedia.org/resource/Hormonal_therapy_(oncology)", "source": "a"}, {"surface": "chemotherapy", "start": 163, "end": 175, "uri": "http://dbpedia.org/resource/Chemotherapy", "source": "a"}, {"surface": "Pain medications", "start": 224, "end": 240, "uri": "http://dbpedia.org/resource/Pain_medication", "source": "a"}, {"surface": "bisphosphonates", "start": 242, "end": 257, "uri": "http://dbpedia.org/resource/Bisphosphonate", "source": "a"}, {"surface": "targeted therapy", "start": 263, "end": 279, "uri": "http://dbpedia.org/resource/Targeted_therapy", "source": "a"}, {"surface": "United States", "start": 450, "end": 463, "uri": "http://dbpedia.org/resource/United_States", "source": "a"}, {"surface": "five-year survival rate", "start": 464, "end": 487, "uri": "http://dbpedia.org/resource/Five-year_survival_rate", "source": "a"}, {"surface": "watchful waiting", "start": 51, "end": 67, "uri": "http://dbpedia.org/resource/Watchful_waiting", "source": "dbpedia_spotlight"}, {"surface": "radiation therapy", "start": 124, "end": 141, "uri": "http://dbpedia.org/resource/Radiation_therapy", "source": "dbpedia_spotlight"}, {"surface": "hormone therapy", "start": 143, "end": 158, "uri": "http://dbpedia.org/resource/Hormone_therapy", "source": "dbpedia_spotlight"}, {"surface": "chemotherapy", "start": 163, "end": 175, "uri": "http://dbpedia.org/resource/Chemotherapy", "source": "dbpedia_spotlight"}, {"surface": "prostate", "start": 199, "end": 207, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "Pain medications", "start": 224, "end": 240, "uri": "http://dbpedia.org/resource/Analgesic", "source": "dbpedia_spotlight"}, {"surface": "bisphosphonates", "start": 242, "end": 257, "uri": "http://dbpedia.org/resource/Bisphosphonate", "source": "dbpedia_spotlight"}, {"surface": "targeted therapy", "start": 263, "end": 279, "uri": "http://dbpedia.org/resource/Targeted_therapy", "source": "dbpedia_spotlight"}, {"surface": "cancer", "start": 385, "end": 391, "uri": "http://dbpedia.org/resource/Cancer", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 410, "end": 425, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "United States", "start": 450, "end": 463, "uri": "http://dbpedia.org/resource/United_States", "source": "dbpedia_spotlight"}, {"surface": "five-year survival rate", "start": 464, "end": 487, "uri": "http://dbpedia.org/resource/Five-year_survival_rate", "source": "dbpedia_spotlight"}, {"surface": "The United States", "start": 446, "end": 463, "uri": "https://calvoritmo.com/tfm/entity/5770975d-a70a-4eed-8792-c902a749e4d2", "source": "spacy"}, {"surface": "five-year", "start": 464, "end": 473, "uri": "https://calvoritmo.com/tfm/entity/478efac5-563b-48ae-a00e-b8a193c79c33", "source": "spacy"}, {"surface": "98%", "start": 491, "end": 494, "uri": "https://calvoritmo.com/tfm/entity/e034ec7d-0c79-485e-b554-0bbb6e96c386", "source": "spacy"}]}, {"text": "Globally, it is the second-most common cancer. It is the fifth-leading cause of cancer-related death in men. In 2018, it was diagnosed in 1.2 million and caused 359,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. One study reported prostate cancer in 30% to 70% of Russian and Japanese men over age 60 who had died of unrelated causes.", "annotations": [{"surface": "developed world", "start": 264, "end": 279, "uri": "http://dbpedia.org/resource/Developed_world", "source": "a"}, {"surface": "developing world", "start": 315, "end": 331, "uri": "http://dbpedia.org/resource/Developing_world", "source": "a"}, {"surface": "cancer", "start": 39, "end": 45, "uri": "http://dbpedia.org/resource/Cancer", "source": "dbpedia_spotlight"}, {"surface": "cancer", "start": 200, "end": 206, "uri": "http://dbpedia.org/resource/Cancer", "source": "dbpedia_spotlight"}, {"surface": "PSA", "start": 421, "end": 424, "uri": "http://dbpedia.org/resource/Prostate-specific_antigen", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 453, "end": 468, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "Russian", "start": 486, "end": 493, "uri": "http://dbpedia.org/resource/Russian_language", "source": "dbpedia_spotlight"}, {"surface": "second", "start": 20, "end": 26, "uri": "https://calvoritmo.com/tfm/entity/cd4cc654-e577-4be2-8414-f5dc1934b12b", "source": "spacy"}, {"surface": "fifth", "start": 57, "end": 62, "uri": "https://calvoritmo.com/tfm/entity/f6c68f78-706b-4349-b123-55dce4708b01", "source": "spacy"}, {"surface": "2018", "start": 112, "end": 116, "uri": "https://calvoritmo.com/tfm/entity/0ee3d1f3-44aa-4a58-86b0-c9e3f7a7c0d1", "source": "spacy"}, {"surface": "1.2 million", "start": 138, "end": 149, "uri": "https://calvoritmo.com/tfm/entity/6a4fd9ad-a5e9-4892-8e98-ff512c06de87", "source": "spacy"}, {"surface": "359,000", "start": 161, "end": 168, "uri": "https://calvoritmo.com/tfm/entity/6a7edaf2-05f0-4816-9d03-d39cfadb070d", "source": "spacy"}, {"surface": "84", "start": 219, "end": 221, "uri": "https://calvoritmo.com/tfm/entity/d6c896a1-fc6a-4a5a-8ee6-c436abc7e86c", "source": "spacy"}, {"surface": "the 1980s and", "start": 370, "end": 383, "uri": "https://calvoritmo.com/tfm/entity/99f43b41-ec1d-4a8d-b8af-b7602872bbac", "source": "spacy"}, {"surface": "1990s", "start": 384, "end": 389, "uri": "https://calvoritmo.com/tfm/entity/dad3aafd-60f6-4685-9114-15ef7d78b17c", "source": "spacy"}, {"surface": "PSA", "start": 421, "end": 424, "uri": "https://calvoritmo.com/tfm/entity/3c82e4a2-6d6f-496e-8d2e-4149aa99d621", "source": "spacy"}, {"surface": "One", "start": 434, "end": 437, "uri": "https://calvoritmo.com/tfm/entity/4eeabee6-d026-4d55-9d92-5730da8bf388", "source": "spacy"}, {"surface": "30% to 70%", "start": 472, "end": 482, "uri": "https://calvoritmo.com/tfm/entity/0417d6ce-d372-4617-902d-3c8fd9a0c58a", "source": "spacy"}, {"surface": "Russian", "start": 486, "end": 493, "uri": "https://calvoritmo.com/tfm/entity/9d481cca-b3b7-4dc7-8b29-a0f41e5f4957", "source": "spacy"}, {"surface": "Japanese", "start": 498, "end": 506, "uri": "https://calvoritmo.com/tfm/entity/9f8dac16-7648-4a9d-99dd-c874daf967a4", "source": "spacy"}, {"surface": "age 60", "start": 516, "end": 522, "uri": "https://calvoritmo.com/tfm/entity/e11944f8-a829-469d-999c-d9465c4157b4", "source": "spacy"}]}], "subsections": [{"title": "Diagnosis", "sectionItems": [{"text": "The American Cancer Society's position regarding early detection by PSA testing is:", "annotations": [{"surface": "American Cancer Society", "start": 4, "end": 27, "uri": "http://dbpedia.org/resource/American_Cancer_Society", "source": "a"}, {"surface": "American Cancer Society", "start": 4, "end": 27, "uri": "http://dbpedia.org/resource/American_Cancer_Society", "source": "dbpedia_spotlight"}, {"surface": "PSA", "start": 68, "end": 71, "uri": "http://dbpedia.org/resource/Prostate-specific_antigen", "source": "dbpedia_spotlight"}, {"surface": "The American Cancer Society's", "start": 0, "end": 29, "uri": "https://calvoritmo.com/tfm/entity/c9d41e3e-b305-4c30-9505-b3df7a9af826", "source": "spacy"}, {"surface": "PSA", "start": 68, "end": 71, "uri": "https://calvoritmo.com/tfm/entity/4dadfa91-094f-46f9-9089-e462b0aea013", "source": "spacy"}]}, {"text": "Research has not yet proven that the potential benefits of testing outweigh the harms of testing and treatment. The American Cancer Society believes that men should not be tested without learning about what we know and don't know about the risks and possible benefits of testing and treatment. Starting at age 50, (45 if African American or brother or father suffered from condition before age 65) talk to your doctor about the pros and cons of testing so you can decide if testing is the right choice for you.'", "annotations": [{"surface": "American Cancer Society", "start": 116, "end": 139, "uri": "http://dbpedia.org/resource/American_Cancer_Society", "source": "dbpedia_spotlight"}, {"surface": "African American", "start": 321, "end": 337, "uri": "http://dbpedia.org/resource/African_Americans", "source": "dbpedia_spotlight"}, {"surface": "age 50", "start": 306, "end": 312, "uri": "https://calvoritmo.com/tfm/entity/ee3412d8-2354-4ec2-8b37-880f23b1e844", "source": "spacy"}, {"surface": "45", "start": 315, "end": 317, "uri": "https://calvoritmo.com/tfm/entity/cdc25efd-a544-423c-a77e-2ebf6f911f1f", "source": "spacy"}, {"surface": "African American", "start": 321, "end": 337, "uri": "https://calvoritmo.com/tfm/entity/6e9ba79d-d2ea-4740-937a-9ed6cd7df6ea", "source": "spacy"}, {"surface": "age 65", "start": 390, "end": 396, "uri": "https://calvoritmo.com/tfm/entity/970e48f4-5791-4fd7-be32-08a1ea14781d", "source": "spacy"}]}, {"text": "Several other tests can be used to gather information about the prostate and the urinary tract. Digital rectal examination may allow a doctor to detect prostate abnormalities. Cystoscopy shows the urinary tract from inside the bladder, using a thin, flexible camera tube inserted in the urethra. Transrectal ultrasonography creates a picture of the prostate using sound waves from a probe in the rectum, but the only test that can fully confirm the diagnosis of prostate cancer is a biopsy, the removal of small pieces of the prostate for microscopic examination.", "annotations": [{"surface": "rectal examination", "start": 104, "end": 122, "uri": "http://dbpedia.org/resource/Rectal_examination", "source": "a"}, {"surface": "Cystoscopy", "start": 176, "end": 186, "uri": "http://dbpedia.org/resource/Cystoscopy", "source": "a"}, {"surface": "urethra", "start": 287, "end": 294, "uri": "http://dbpedia.org/resource/Urethra", "source": "a"}, {"surface": "Transrectal ultrasonography", "start": 296, "end": 323, "uri": "http://dbpedia.org/resource/Transrectal_ultrasonography", "source": "a"}, {"surface": "biopsy", "start": 483, "end": 489, "uri": "http://dbpedia.org/resource/Biopsy", "source": "a"}, {"surface": "prostate", "start": 64, "end": 72, "uri": "http://dbpedia.org/resource/Rectal_examination", "source": "dbpedia_spotlight"}, {"surface": "urinary tract", "start": 81, "end": 94, "uri": "http://dbpedia.org/resource/Urinary_system", "source": "dbpedia_spotlight"}, {"surface": "Digital rectal examination", "start": 96, "end": 122, "uri": "http://dbpedia.org/resource/Rectal_examination", "source": "dbpedia_spotlight"}, {"surface": "prostate", "start": 152, "end": 160, "uri": "http://dbpedia.org/resource/Rectal_examination", "source": "dbpedia_spotlight"}, {"surface": "Cystoscopy", "start": 176, "end": 186, "uri": "http://dbpedia.org/resource/Cystoscopy", "source": "dbpedia_spotlight"}, {"surface": "urinary tract", "start": 197, "end": 210, "uri": "http://dbpedia.org/resource/Urinary_system", "source": "dbpedia_spotlight"}, {"surface": "bladder", "start": 227, "end": 234, "uri": "http://dbpedia.org/resource/Urinary_bladder", "source": "dbpedia_spotlight"}, {"surface": "camera tube", "start": 259, "end": 270, "uri": "http://dbpedia.org/resource/Video_camera_tube", "source": "dbpedia_spotlight"}, {"surface": "urethra", "start": 287, "end": 294, "uri": "http://dbpedia.org/resource/Urethra", "source": "dbpedia_spotlight"}, {"surface": "Transrectal ultrasonography", "start": 296, "end": 323, "uri": "http://dbpedia.org/resource/Transrectal_ultrasonography", "source": "dbpedia_spotlight"}, {"surface": "prostate", "start": 349, "end": 357, "uri": "http://dbpedia.org/resource/Rectal_examination", "source": "dbpedia_spotlight"}, {"surface": "rectum", "start": 396, "end": 402, "uri": "http://dbpedia.org/resource/Rectum", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 462, "end": 477, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "biopsy", "start": 483, "end": 489, "uri": "http://dbpedia.org/resource/Biopsy", "source": "dbpedia_spotlight"}, {"surface": "prostate", "start": 526, "end": 534, "uri": "http://dbpedia.org/resource/Rectal_examination", "source": "dbpedia_spotlight"}, {"surface": "Digital", "start": 96, "end": 103, "uri": "https://calvoritmo.com/tfm/entity/ff756da1-c673-4142-bbaf-f164fa8335cc", "source": "spacy"}]}], "subsections": [{"title": "Imaging", "sectionItems": [{"text": "Ultrasound and magnetic resonance imaging (MRI) are the two main imaging methods used for prostate cancer detection.", "annotations": [{"surface": "Ultrasound", "start": 0, "end": 10, "uri": "http://dbpedia.org/resource/Medical_ultrasound", "source": "a"}, {"surface": "magnetic resonance imaging", "start": 15, "end": 41, "uri": "http://dbpedia.org/resource/Magnetic_resonance_imaging", "source": "a"}, {"surface": "Ultrasound", "start": 0, "end": 10, "uri": "http://dbpedia.org/resource/Ultrasound", "source": "dbpedia_spotlight"}, {"surface": "magnetic resonance imaging (MRI)", "start": 15, "end": 47, "uri": "http://dbpedia.org/resource/Magnetic_resonance_imaging", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 90, "end": 105, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "two", "start": 56, "end": 59, "uri": "https://calvoritmo.com/tfm/entity/e787eed1-88aa-4448-8a5a-dda67ae3d1f5", "source": "spacy"}]}], "subsections": [{"title": "MRI", "sectionItems": [], "subsections": [{"title": "Appearance of prostate on MRI", "sectionItems": [{"text": "On MRI, the central and transitional zones both have lower T2 signal than the peripheral zone. Since the central and transitional zones cannot be distinguished from each other, they can be best described as the central gland on MRI. Thus, the peripheral gland has a higher signal on T2WI than the central gland. In the peripheral gland, prostate cancer appears as a low-intensity lesion. However, in the central gland, low-intensity lesions cannot be distinguished from the low-intensity central gland. Diffusion restriction is instrumental in identifying and characterizing central gland lesions. Combined diffusion-weighted (DW) imaging and dynamic contrast-enhanced MRI for distinguish malignant from benign prostate lesions can be used. The merged  images,  of  DW  and  MRI  with  dynamic  contrast  enhancement, can  visualise areas with low signal intensity and fast wash-out effect - characteristic of carcinomas. Lymphadenopathy can be seen best on postcontrast, fat-suppressed T1WI. Other regions can be described on MRI. The anterior fibromuscular stroma and the prostate capsule along the posterior and lateral prostate have a low T2WI signal, in contrast with the bright signal of the peripheral zone. Extraprostatic extension can be seen with disruption of capsule integrity.", "annotations": [{"surface": "lesion", "start": 380, "end": 386, "uri": "http://dbpedia.org/resource/Lesion", "source": "a"}, {"surface": "Lymphadenopathy", "start": 922, "end": 937, "uri": "http://dbpedia.org/resource/Lymphadenopathy", "source": "a"}, {"surface": "MRI", "start": 3, "end": 6, "uri": "http://dbpedia.org/resource/Magnetic_resonance_imaging", "source": "dbpedia_spotlight"}, {"surface": "MRI", "start": 228, "end": 231, "uri": "http://dbpedia.org/resource/Magnetic_resonance_imaging", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 337, "end": 352, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "lesion", "start": 380, "end": 386, "uri": "http://dbpedia.org/resource/Lesion", "source": "dbpedia_spotlight"}, {"surface": "DW", "start": 627, "end": 629, "uri": "http://dbpedia.org/resource/Data_warehouse", "source": "dbpedia_spotlight"}, {"surface": "MRI", "start": 669, "end": 672, "uri": "http://dbpedia.org/resource/Magnetic_resonance_imaging", "source": "dbpedia_spotlight"}, {"surface": "malignant", "start": 689, "end": 698, "uri": "http://dbpedia.org/resource/Malignancy", "source": "dbpedia_spotlight"}, {"surface": "prostate", "start": 711, "end": 719, "uri": "http://dbpedia.org/resource/Prostate", "source": "dbpedia_spotlight"}, {"surface": "DW", "start": 766, "end": 768, "uri": "http://dbpedia.org/resource/Data_warehouse", "source": "dbpedia_spotlight"}, {"surface": "MRI", "start": 775, "end": 778, "uri": "http://dbpedia.org/resource/Magnetic_resonance_imaging", "source": "dbpedia_spotlight"}, {"surface": "Lymphadenopathy", "start": 922, "end": 937, "uri": "http://dbpedia.org/resource/Lymphadenopathy", "source": "dbpedia_spotlight"}, {"surface": "MRI", "start": 1027, "end": 1030, "uri": "http://dbpedia.org/resource/Magnetic_resonance_imaging", "source": "dbpedia_spotlight"}, {"surface": "stroma", "start": 1059, "end": 1065, "uri": "http://dbpedia.org/resource/Stromal_cell", "source": "dbpedia_spotlight"}, {"surface": "prostate", "start": 1074, "end": 1082, "uri": "http://dbpedia.org/resource/Prostate", "source": "dbpedia_spotlight"}, {"surface": "capsule", "start": 1083, "end": 1090, "uri": "http://dbpedia.org/resource/Joint_capsule", "source": "dbpedia_spotlight"}, {"surface": "prostate", "start": 1123, "end": 1131, "uri": "http://dbpedia.org/resource/Prostate", "source": "dbpedia_spotlight"}, {"surface": "capsule", "start": 1271, "end": 1278, "uri": "http://dbpedia.org/resource/Joint_capsule", "source": "dbpedia_spotlight"}, {"surface": "T2WI", "start": 283, "end": 287, "uri": "https://calvoritmo.com/tfm/entity/500d1925-6da9-4253-8a3d-8bb34b5580ff", "source": "spacy"}, {"surface": "DW", "start": 627, "end": 629, "uri": "https://calvoritmo.com/tfm/entity/56ee61b9-c267-41c7-a5a3-7fa5f2fa992c", "source": "spacy"}, {"surface": "T1WI", "start": 987, "end": 991, "uri": "https://calvoritmo.com/tfm/entity/ed291cf5-bd29-4854-961d-0fdceb50d50a", "source": "spacy"}, {"surface": "T2WI", "start": 1143, "end": 1147, "uri": "https://calvoritmo.com/tfm/entity/79aa09f4-6a53-4d26-b02a-17ef3dfbc567", "source": "spacy"}]}], "subsections": [{"title": "MRI for the detection of prostate cancer", "sectionItems": [{"text": "As of 2011, MRI was used to identify targets for prostate biopsy using fusion MRI with ultrasound (US) or MRI-guidance alone. An MRI alone will correctly identify 91% of men with clinically significant prostate cancer but will misclassify 63% of men at risk for prostate cancer as having clinically significant prostate cancer. An MRI-targeted biopsy will correctly identify 80% of men with prostate cancer. However, it will classify 6% of men at risk for prostate cancer as having clinically significant prostate cancer. Detection of clinically insignificant cancer has been shown to be decreased when MRI-targeted biopsy is combined with standard biopsy for men with positive results on MRI, as compared with a standard biopsy method.", "annotations": [{"surface": "MRI", "start": 12, "end": 15, "uri": "http://dbpedia.org/resource/Magnetic_resonance_imaging", "source": "dbpedia_spotlight"}, {"surface": "prostate", "start": 49, "end": 57, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "biopsy", "start": 58, "end": 64, "uri": "http://dbpedia.org/resource/Biopsy", "source": "dbpedia_spotlight"}, {"surface": "MRI", "start": 78, "end": 81, "uri": "http://dbpedia.org/resource/Magnetic_resonance_imaging", "source": "dbpedia_spotlight"}, {"surface": "ultrasound", "start": 87, "end": 97, "uri": "http://dbpedia.org/resource/Medical_ultrasound", "source": "dbpedia_spotlight"}, {"surface": "MRI", "start": 129, "end": 132, "uri": "http://dbpedia.org/resource/Magnetic_resonance_imaging", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 202, "end": 217, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 262, "end": 277, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 311, "end": 326, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "biopsy", "start": 344, "end": 350, "uri": "http://dbpedia.org/resource/Biopsy", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 391, "end": 406, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 456, "end": 471, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 505, "end": 520, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "cancer", "start": 560, "end": 566, "uri": "http://dbpedia.org/resource/Cancer", "source": "dbpedia_spotlight"}, {"surface": "biopsy", "start": 616, "end": 622, "uri": "http://dbpedia.org/resource/Biopsy", "source": "dbpedia_spotlight"}, {"surface": "biopsy", "start": 649, "end": 655, "uri": "http://dbpedia.org/resource/Biopsy", "source": "dbpedia_spotlight"}, {"surface": "MRI", "start": 689, "end": 692, "uri": "http://dbpedia.org/resource/Magnetic_resonance_imaging", "source": "dbpedia_spotlight"}, {"surface": "biopsy", "start": 722, "end": 728, "uri": "http://dbpedia.org/resource/Biopsy", "source": "dbpedia_spotlight"}, {"surface": "2011", "start": 6, "end": 10, "uri": "https://calvoritmo.com/tfm/entity/4bc0c77c-ba7d-43b3-bc1d-3993ae9a8d34", "source": "spacy"}, {"surface": "US", "start": 99, "end": 101, "uri": "https://calvoritmo.com/tfm/entity/87913bdb-972c-499f-b870-648a648abc99", "source": "spacy"}, {"surface": "91%", "start": 163, "end": 166, "uri": "https://calvoritmo.com/tfm/entity/ba2384d0-e710-4a20-8c4e-755f894d3305", "source": "spacy"}, {"surface": "63%", "start": 239, "end": 242, "uri": "https://calvoritmo.com/tfm/entity/39b1d10e-3de5-4759-930e-1fe937a96efd", "source": "spacy"}, {"surface": "80%", "start": 375, "end": 378, "uri": "https://calvoritmo.com/tfm/entity/e8f0bfef-371f-4e2a-b379-ba92f9b8843d", "source": "spacy"}, {"surface": "6%", "start": 434, "end": 436, "uri": "https://calvoritmo.com/tfm/entity/d4f01e9b-a348-49a0-8ef0-0e95a364a03c", "source": "spacy"}]}, {"text": "Following an MRI, regions of interest within the scan which may be cancer are often graded on a likelihood scale between 1 and 5. One such scale is the prostate imaging-reporting and data system (PI-RADS) scale which defines standards of clinical service for multiparametric MRI (mpMRI), including image creation and reporting. PI-RADS version 2 scoring has shown a specificity and sensitivity of 73% and 95%, respectively, for detection of prostate cancer.", "annotations": [{"surface": "prostate imaging-reporting and data system", "start": 152, "end": 194, "uri": "http://dbpedia.org/resource/PI-RADS", "source": "a"}, {"surface": "MRI", "start": 13, "end": 16, "uri": "http://dbpedia.org/resource/Magnetic_resonance_imaging", "source": "dbpedia_spotlight"}, {"surface": "cancer", "start": 67, "end": 73, "uri": "http://dbpedia.org/resource/Cancer", "source": "dbpedia_spotlight"}, {"surface": "prostate", "start": 152, "end": 160, "uri": "http://dbpedia.org/resource/Prostate", "source": "dbpedia_spotlight"}, {"surface": "PI-RADS", "start": 196, "end": 203, "uri": "http://dbpedia.org/resource/PI-RADS", "source": "dbpedia_spotlight"}, {"surface": "MRI", "start": 275, "end": 278, "uri": "http://dbpedia.org/resource/Magnetic_resonance_imaging", "source": "dbpedia_spotlight"}, {"surface": "PI-RADS", "start": 328, "end": 335, "uri": "http://dbpedia.org/resource/PI-RADS", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 441, "end": 456, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "scan", "start": 49, "end": 53, "uri": "https://calvoritmo.com/tfm/entity/7cf59127-4c79-4d91-9dd6-f55649c5a60c", "source": "spacy"}, {"surface": "between 1 and 5", "start": 113, "end": 128, "uri": "https://calvoritmo.com/tfm/entity/50938a76-d517-436d-942a-600d5e5ec565", "source": "spacy"}, {"surface": "One", "start": 130, "end": 133, "uri": "https://calvoritmo.com/tfm/entity/4bc78b77-0b4d-4bd2-a3f0-a21e2e5a1c8b", "source": "spacy"}, {"surface": "PI-RADS", "start": 196, "end": 203, "uri": "https://calvoritmo.com/tfm/entity/6e8afbdc-75f8-46a3-8652-1ed2b05b2d3b", "source": "spacy"}, {"surface": "PI-RADS", "start": 328, "end": 335, "uri": "https://calvoritmo.com/tfm/entity/de4a3dd1-c425-4e3c-beab-2ee189c0b13a", "source": "spacy"}, {"surface": "2", "start": 344, "end": 345, "uri": "https://calvoritmo.com/tfm/entity/535f41e8-6be3-4990-8b9f-027a87e5ca37", "source": "spacy"}, {"surface": "73% and 95%", "start": 397, "end": 408, "uri": "https://calvoritmo.com/tfm/entity/75e4b568-3176-4fe3-9e63-876bbac2b1d4", "source": "spacy"}]}, {"text": "When an MRI is used to decide whether to do a biopsy in men who have had a prior biopsy, it is 5% more likely to make a correct diagnosis than a standard biopsy and is 12% more likely to be correct for men who may or may not have had a prior biopsy. In men who have had a negative biopsy, this combination is 44% more likely to lead to a correct diagnosis.", "annotations": [{"surface": "MRI", "start": 8, "end": 11, "uri": "http://dbpedia.org/resource/Magnetic_resonance_imaging", "source": "dbpedia_spotlight"}, {"surface": "biopsy", "start": 46, "end": 52, "uri": "http://dbpedia.org/resource/Biopsy", "source": "dbpedia_spotlight"}, {"surface": "biopsy", "start": 81, "end": 87, "uri": "http://dbpedia.org/resource/Biopsy", "source": "dbpedia_spotlight"}, {"surface": "biopsy", "start": 154, "end": 160, "uri": "http://dbpedia.org/resource/Biopsy", "source": "dbpedia_spotlight"}, {"surface": "biopsy", "start": 242, "end": 248, "uri": "http://dbpedia.org/resource/Biopsy", "source": "dbpedia_spotlight"}, {"surface": "biopsy", "start": 281, "end": 287, "uri": "http://dbpedia.org/resource/Biopsy", "source": "dbpedia_spotlight"}, {"surface": "5%", "start": 95, "end": 97, "uri": "https://calvoritmo.com/tfm/entity/174b69fe-5ac9-4874-888d-9e549b1ed9e4", "source": "spacy"}, {"surface": "12%", "start": 168, "end": 171, "uri": "https://calvoritmo.com/tfm/entity/c9ecfc8c-7e6a-4b11-9026-33f8206e3c4e", "source": "spacy"}, {"surface": "44%", "start": 309, "end": 312, "uri": "https://calvoritmo.com/tfm/entity/1535c4d1-0162-4d46-b3cb-0bdc593eba75", "source": "spacy"}]}], "subsections": [{"title": "Biopsy", "sectionItems": [{"text": "If cancer is suspected, a biopsy is offered expediently. During a biopsy, a urologist or radiologist obtains tissue samples from the prostate via either the rectum or the perineum. A biopsy gun inserts and removes special hollow-core needles (usually three to six on each side of the prostate) in less than a second. Prostate biopsies are routinely done on an outpatient basis and rarely require hospitalization. Systematic biopsies correctly identify 63% of men as having clinically significant prostate cancer but will miss the rest. For men at risk for prostate cancer, biopsy will not misclassify any of the men as having clinically significant prostate cancer.", "annotations": [{"surface": "urologist", "start": 76, "end": 85, "uri": "http://dbpedia.org/resource/Urology", "source": "a"}, {"surface": "radiologist", "start": 89, "end": 100, "uri": "http://dbpedia.org/resource/Radiology", "source": "a"}, {"surface": "cancer", "start": 3, "end": 9, "uri": "http://dbpedia.org/resource/Cancer", "source": "dbpedia_spotlight"}, {"surface": "biopsy", "start": 26, "end": 32, "uri": "http://dbpedia.org/resource/Biopsy", "source": "dbpedia_spotlight"}, {"surface": "biopsy", "start": 66, "end": 72, "uri": "http://dbpedia.org/resource/Biopsy", "source": "dbpedia_spotlight"}, {"surface": "urologist", "start": 76, "end": 85, "uri": "http://dbpedia.org/resource/Urology", "source": "dbpedia_spotlight"}, {"surface": "radiologist", "start": 89, "end": 100, "uri": "http://dbpedia.org/resource/Radiology", "source": "dbpedia_spotlight"}, {"surface": "prostate", "start": 133, "end": 141, "uri": "http://dbpedia.org/resource/Prostate", "source": "dbpedia_spotlight"}, {"surface": "rectum", "start": 157, "end": 163, "uri": "http://dbpedia.org/resource/Rectum", "source": "dbpedia_spotlight"}, {"surface": "perineum", "start": 171, "end": 179, "uri": "http://dbpedia.org/resource/Perineum", "source": "dbpedia_spotlight"}, {"surface": "biopsy", "start": 183, "end": 189, "uri": "http://dbpedia.org/resource/Biopsy", "source": "dbpedia_spotlight"}, {"surface": "prostate", "start": 284, "end": 292, "uri": "http://dbpedia.org/resource/Prostate", "source": "dbpedia_spotlight"}, {"surface": "Prostate biopsies", "start": 317, "end": 334, "uri": "http://dbpedia.org/resource/Prostate_biopsy", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 496, "end": 511, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 556, "end": 571, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "biopsy", "start": 573, "end": 579, "uri": "http://dbpedia.org/resource/Biopsy", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 649, "end": 664, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "three to six", "start": 251, "end": 263, "uri": "https://calvoritmo.com/tfm/entity/e1981958-612a-4f7c-9faf-7406dbebeb08", "source": "spacy"}, {"surface": "less than a second", "start": 297, "end": 315, "uri": "https://calvoritmo.com/tfm/entity/5cc316f1-c563-4a21-b5aa-f586ae91f99a", "source": "spacy"}, {"surface": "63%", "start": 452, "end": 455, "uri": "https://calvoritmo.com/tfm/entity/2240ead7-34e4-4ab3-9ed1-4bcd9b70b7e6", "source": "spacy"}]}, {"text": "Antibiotics should be used to prevent complications such as fever, urinary tract infections, and sepsis even if the most appropriate course or dose is undefined. About 55% of men report discomfort during prostate biopsy.", "annotations": [{"surface": "Antibiotics", "start": 0, "end": 11, "uri": "http://dbpedia.org/resource/Antibiotic", "source": "a"}, {"surface": "fever", "start": 60, "end": 65, "uri": "http://dbpedia.org/resource/Fever", "source": "a"}, {"surface": "urinary tract infections", "start": 67, "end": 91, "uri": "http://dbpedia.org/resource/Urinary_tract_infection", "source": "a"}, {"surface": "sepsis", "start": 97, "end": 103, "uri": "http://dbpedia.org/resource/Sepsis", "source": "a"}, {"surface": "Antibiotics", "start": 0, "end": 11, "uri": "http://dbpedia.org/resource/Antibiotic", "source": "dbpedia_spotlight"}, {"surface": "fever", "start": 60, "end": 65, "uri": "http://dbpedia.org/resource/Fever", "source": "dbpedia_spotlight"}, {"surface": "urinary tract infections", "start": 67, "end": 91, "uri": "http://dbpedia.org/resource/Urinary_tract_infection", "source": "dbpedia_spotlight"}, {"surface": "sepsis", "start": 97, "end": 103, "uri": "http://dbpedia.org/resource/Sepsis", "source": "dbpedia_spotlight"}, {"surface": "prostate", "start": 204, "end": 212, "uri": "http://dbpedia.org/resource/Prostate", "source": "dbpedia_spotlight"}, {"surface": "biopsy", "start": 213, "end": 219, "uri": "http://dbpedia.org/resource/Biopsy", "source": "dbpedia_spotlight"}, {"surface": "About 55%", "start": 162, "end": 171, "uri": "https://calvoritmo.com/tfm/entity/f8163762-fc8f-4ef9-b0e5-535549cb7b9d", "source": "spacy"}]}], "subsections": [{"title": "Histopathologic diagnosis", "sectionItems": [{"text": "A histopathologic diagnosis mainly includes assessment of whether a cancer exists, as well as any subdiagnosis, if possible. Histopathologic subdiagnosis has implications for the possibility and methodology of Gleason scoring. The most common histopathological subdiagnosis is acinar adenocarcinoma, constituting 93% of diagnoses. The most common form of acinar adenocarcinoma, in turn, is 'adenocarcinoma, not otherwise specified', also termed conventional, or usual acinar adenocarcinoma.", "annotations": [{"surface": "histopathologic", "start": 2, "end": 17, "uri": "http://dbpedia.org/resource/Histopathology", "source": "a"}, {"surface": "Gleason scoring", "start": 210, "end": 225, "uri": "http://dbpedia.org/resource/Gleason_score", "source": "a"}, {"surface": "acinar adenocarcinoma", "start": 277, "end": 298, "uri": "http://dbpedia.org/resource/Acinar_adenocarcinoma", "source": "a"}, {"surface": "histopathologic", "start": 2, "end": 17, "uri": "http://dbpedia.org/resource/Histopathology", "source": "dbpedia_spotlight"}, {"surface": "cancer", "start": 68, "end": 74, "uri": "http://dbpedia.org/resource/Cancer", "source": "dbpedia_spotlight"}, {"surface": "Gleason scoring", "start": 210, "end": 225, "uri": "http://dbpedia.org/resource/Gleason_grading_system", "source": "dbpedia_spotlight"}, {"surface": "histopathological", "start": 243, "end": 260, "uri": "http://dbpedia.org/resource/Histopathology", "source": "dbpedia_spotlight"}, {"surface": "adenocarcinoma", "start": 284, "end": 298, "uri": "http://dbpedia.org/resource/Adenocarcinoma", "source": "dbpedia_spotlight"}, {"surface": "adenocarcinoma", "start": 362, "end": 376, "uri": "http://dbpedia.org/resource/Adenocarcinoma", "source": "dbpedia_spotlight"}, {"surface": "adenocarcinoma", "start": 391, "end": 405, "uri": "http://dbpedia.org/resource/Adenocarcinoma", "source": "dbpedia_spotlight"}, {"surface": "adenocarcinoma", "start": 475, "end": 489, "uri": "http://dbpedia.org/resource/Adenocarcinoma", "source": "dbpedia_spotlight"}, {"surface": "Gleason", "start": 210, "end": 217, "uri": "https://calvoritmo.com/tfm/entity/b0a6d7ab-3308-4a33-ab0b-651e75b94435", "source": "spacy"}, {"surface": "93%", "start": 313, "end": 316, "uri": "https://calvoritmo.com/tfm/entity/048409c5-8b81-4274-915e-e048db7b0b76", "source": "spacy"}]}], "subsections": [{"title": "Management", "sectionItems": [{"text": "The first decision is whether treatment is needed. Low-grade forms found in elderly men often grow so slowly that treatment is not required. Treatment may be inappropriate if a person has other serious health problems or is not expected to live long enough for symptoms to appear. Approaches in which treatment is postponed are termed 'expectant management'. Expectant management is divided into two approaches: Watchful waiting, which has palliative intent (aims to treat symptoms only), and active surveillance, which has curative intent (aims to prevent the cancer from advancing).", "annotations": [{"surface": "Watchful waiting", "start": 412, "end": 428, "uri": "http://dbpedia.org/resource/Watchful_waiting", "source": "a"}, {"surface": "palliative intent", "start": 440, "end": 457, "uri": "http://dbpedia.org/resource/Palliative_care", "source": "a"}, {"surface": "active surveillance", "start": 493, "end": 512, "uri": "http://dbpedia.org/resource/Active_surveillance_of_prostate_cancer", "source": "a"}, {"surface": "expectant management", "start": 336, "end": 356, "uri": "http://dbpedia.org/resource/Watchful_waiting", "source": "dbpedia_spotlight"}, {"surface": "Expectant management", "start": 359, "end": 379, "uri": "http://dbpedia.org/resource/Watchful_waiting", "source": "dbpedia_spotlight"}, {"surface": "Watchful waiting", "start": 412, "end": 428, "uri": "http://dbpedia.org/resource/Watchful_waiting", "source": "dbpedia_spotlight"}, {"surface": "palliative", "start": 440, "end": 450, "uri": "http://dbpedia.org/resource/Palliative_care", "source": "dbpedia_spotlight"}, {"surface": "cancer", "start": 561, "end": 567, "uri": "http://dbpedia.org/resource/Cancer", "source": "dbpedia_spotlight"}, {"surface": "first", "start": 4, "end": 9, "uri": "https://calvoritmo.com/tfm/entity/b42084f5-30eb-4dcd-b4f4-6a71373b2df9", "source": "spacy"}, {"surface": "two", "start": 396, "end": 399, "uri": "https://calvoritmo.com/tfm/entity/dd280f6f-3063-44f0-936a-a823406ef55e", "source": "spacy"}]}, {"text": "Which option is best depends on disease stage, the Gleason score, and the PSA level. Other important factors are age, general health and a person's views about potential treatments and their possible side effects. Because most treatments can have significant side effects, such as erectile dysfunction and urinary incontinence, treatment discussions often focus on balancing the goals of therapy with the risks of lifestyle alterations. A 2017 review found that more research focused on person-centered outcomes is needed to guide patients. A combination of treatment options is often recommended.", "annotations": [{"surface": "side effects", "start": 259, "end": 271, "uri": "http://dbpedia.org/resource/Adverse_effect_(medicine)", "source": "a"}, {"surface": "erectile dysfunction", "start": 281, "end": 301, "uri": "http://dbpedia.org/resource/Erectile_dysfunction", "source": "a"}, {"surface": "urinary incontinence", "start": 306, "end": 326, "uri": "http://dbpedia.org/resource/Urinary_incontinence", "source": "a"}, {"surface": "Gleason score", "start": 51, "end": 64, "uri": "http://dbpedia.org/resource/Gleason_grading_system", "source": "dbpedia_spotlight"}, {"surface": "PSA", "start": 74, "end": 77, "uri": "http://dbpedia.org/resource/Prostate-specific_antigen", "source": "dbpedia_spotlight"}, {"surface": "erectile dysfunction", "start": 281, "end": 301, "uri": "http://dbpedia.org/resource/Erectile_dysfunction", "source": "dbpedia_spotlight"}, {"surface": "urinary incontinence", "start": 306, "end": 326, "uri": "http://dbpedia.org/resource/Urinary_incontinence", "source": "dbpedia_spotlight"}, {"surface": "Gleason", "start": 51, "end": 58, "uri": "https://calvoritmo.com/tfm/entity/f07ec592-12d5-46cc-866e-a103566d7c72", "source": "spacy"}, {"surface": "PSA", "start": 74, "end": 77, "uri": "https://calvoritmo.com/tfm/entity/79739f9a-3758-4455-981c-39f026b3cf13", "source": "spacy"}, {"surface": "2017", "start": 439, "end": 443, "uri": "https://calvoritmo.com/tfm/entity/20d035fe-85a0-4b33-b62b-0690ae32cc88", "source": "spacy"}]}, {"text": "Guidelines for specific clinical situations require estimation of life expectancy. As average life expectancy increases due to advances in the treatment of other diseases, more patients will live long enough for their prostate cancer to express symptoms. An 18-item questionnaire was proposed to learn whether patients have adequate knowledge and understanding of their treatment options. In one 2015 study, most of those who were newly diagnosed correctly answered fewer than half of the questions.", "annotations": [{"surface": "life expectancy", "start": 66, "end": 81, "uri": "http://dbpedia.org/resource/Life_expectancy", "source": "dbpedia_spotlight"}, {"surface": "life expectancy", "start": 94, "end": 109, "uri": "http://dbpedia.org/resource/Life_expectancy", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 218, "end": 233, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "18", "start": 258, "end": 260, "uri": "https://calvoritmo.com/tfm/entity/265410e0-283e-4c1e-86ab-ad9442c311f9", "source": "spacy"}, {"surface": "one 2015", "start": 392, "end": 400, "uri": "https://calvoritmo.com/tfm/entity/666c4d71-70f7-4879-af79-a8d3b8447446", "source": "spacy"}, {"surface": "fewer than half", "start": 466, "end": 481, "uri": "https://calvoritmo.com/tfm/entity/82c02ac9-0612-4891-9ad1-bf415ebe6123", "source": "spacy"}]}, {"text": "The widespread use of PSA screening in the US has resulted in diagnosis at earlier age and cancer stage, but almost all cases are still diagnosed after age 65, while about 25% are diagnosed after age 75. Though US National Comprehensive Cancer Network guidelines recommend using life expectancy to help make treatment decisions, in practice, many elderly patients are not offered curative treatment options such as radical prostatectomy or radiation therapy and are instead treated with hormonal therapy or watchful waiting.", "annotations": [{"surface": "radical prostatectomy", "start": 415, "end": 436, "uri": "http://dbpedia.org/resource/Prostatectomy", "source": "a"}, {"surface": "radiation therapy", "start": 440, "end": 457, "uri": "http://dbpedia.org/resource/Radiation_therapy", "source": "a"}, {"surface": "hormonal therapy", "start": 487, "end": 503, "uri": "http://dbpedia.org/resource/Hormonal_therapy_(oncology)", "source": "a"}, {"surface": "PSA", "start": 22, "end": 25, "uri": "http://dbpedia.org/resource/Prostate-specific_antigen", "source": "dbpedia_spotlight"}, {"surface": "screening", "start": 26, "end": 35, "uri": "http://dbpedia.org/resource/Cancer_screening", "source": "dbpedia_spotlight"}, {"surface": "cancer stage", "start": 91, "end": 103, "uri": "http://dbpedia.org/resource/Cancer_staging", "source": "dbpedia_spotlight"}, {"surface": "National Comprehensive Cancer Network", "start": 214, "end": 251, "uri": "http://dbpedia.org/resource/National_Comprehensive_Cancer_Network", "source": "dbpedia_spotlight"}, {"surface": "life expectancy", "start": 279, "end": 294, "uri": "http://dbpedia.org/resource/Life_expectancy", "source": "dbpedia_spotlight"}, {"surface": "prostatectomy", "start": 423, "end": 436, "uri": "http://dbpedia.org/resource/Prostatectomy", "source": "dbpedia_spotlight"}, {"surface": "radiation therapy", "start": 440, "end": 457, "uri": "http://dbpedia.org/resource/Radiation_therapy", "source": "dbpedia_spotlight"}, {"surface": "hormonal therapy", "start": 487, "end": 503, "uri": "http://dbpedia.org/resource/Hormone_therapy", "source": "dbpedia_spotlight"}, {"surface": "watchful waiting", "start": 507, "end": 523, "uri": "http://dbpedia.org/resource/Watchful_waiting", "source": "dbpedia_spotlight"}, {"surface": "PSA", "start": 22, "end": 25, "uri": "https://calvoritmo.com/tfm/entity/b1f590d8-c772-4128-b353-8e1139806583", "source": "spacy"}, {"surface": "US", "start": 43, "end": 45, "uri": "https://calvoritmo.com/tfm/entity/7d1dab56-5880-4625-8648-9e9b00f65406", "source": "spacy"}, {"surface": "age 65", "start": 152, "end": 158, "uri": "https://calvoritmo.com/tfm/entity/3fe85d31-a52f-44f6-ae6d-7e228cf4566d", "source": "spacy"}, {"surface": "about 25%", "start": 166, "end": 175, "uri": "https://calvoritmo.com/tfm/entity/24c9e9bc-ef24-4654-93bd-7e2d62d4a37c", "source": "spacy"}, {"surface": "age 75", "start": 196, "end": 202, "uri": "https://calvoritmo.com/tfm/entity/3aad9e91-f91e-47d6-bd38-7c6b7e6c9e02", "source": "spacy"}, {"surface": "US National Comprehensive Cancer Network", "start": 211, "end": 251, "uri": "https://calvoritmo.com/tfm/entity/64a25172-8476-4fd2-b5fb-661e935d71cf", "source": "spacy"}]}], "subsections": [{"title": "Active treatment", "sectionItems": [{"text": "Both surgical and nonsurgical treatments are available, but treatment can be difficult, and combinations can be used. Treatment by external beam radiation therapy, brachytherapy, cryosurgery, high-intensity focused ultrasound, and prostatectomy are, in general, offered to men whose cancer remains within the prostate. Hormonal therapy and chemotherapy are often reserved for metastatic disease. Exceptions include local or metastasis-directed therapy with radiation may be used for advanced tumors with limited metastasis. Hormonal therapy is used for some early-stage tumors. Cryotherapy (the process of freezing the tumor), hormonal therapy, and chemotherapy may be offered if initial treatment fails and the cancer progresses. Sipuleucel-T, a cancer vaccine, was reported to offer a four-month increase in survival in metastatic prostate cancer, but the marketing authorisation for it was withdrawn on 19 May 2015.", "annotations": [{"surface": "external beam radiation therapy", "start": 131, "end": 162, "uri": "http://dbpedia.org/resource/External_beam_radiotherapy", "source": "a"}, {"surface": "brachytherapy", "start": 164, "end": 177, "uri": "http://dbpedia.org/resource/Prostate_brachytherapy", "source": "a"}, {"surface": "cryosurgery", "start": 179, "end": 190, "uri": "http://dbpedia.org/resource/Cryosurgery", "source": "a"}, {"surface": "high-intensity focused ultrasound", "start": 192, "end": 225, "uri": "http://dbpedia.org/resource/High-intensity_focused_ultrasound", "source": "a"}, {"surface": "Cryotherapy", "start": 578, "end": 589, "uri": "http://dbpedia.org/resource/Cryotherapy", "source": "a"}, {"surface": "Sipuleucel-T", "start": 731, "end": 743, "uri": "http://dbpedia.org/resource/Sipuleucel-T", "source": "a"}, {"surface": "cancer vaccine", "start": 747, "end": 761, "uri": "http://dbpedia.org/resource/Cancer_vaccine", "source": "a"}, {"surface": "external beam radiation therapy", "start": 131, "end": 162, "uri": "http://dbpedia.org/resource/External_beam_radiotherapy", "source": "dbpedia_spotlight"}, {"surface": "brachytherapy", "start": 164, "end": 177, "uri": "http://dbpedia.org/resource/Brachytherapy", "source": "dbpedia_spotlight"}, {"surface": "cryosurgery", "start": 179, "end": 190, "uri": "http://dbpedia.org/resource/Cryosurgery", "source": "dbpedia_spotlight"}, {"surface": "high-intensity focused ultrasound", "start": 192, "end": 225, "uri": "http://dbpedia.org/resource/High-intensity_focused_ultrasound", "source": "dbpedia_spotlight"}, {"surface": "prostatectomy", "start": 231, "end": 244, "uri": "http://dbpedia.org/resource/Prostatectomy", "source": "dbpedia_spotlight"}, {"surface": "cancer", "start": 283, "end": 289, "uri": "http://dbpedia.org/resource/Cancer", "source": "dbpedia_spotlight"}, {"surface": "prostate", "start": 309, "end": 317, "uri": "http://dbpedia.org/resource/Prostate", "source": "dbpedia_spotlight"}, {"surface": "Hormonal therapy", "start": 319, "end": 335, "uri": "http://dbpedia.org/resource/Hormone_therapy", "source": "dbpedia_spotlight"}, {"surface": "chemotherapy", "start": 340, "end": 352, "uri": "http://dbpedia.org/resource/Chemotherapy", "source": "dbpedia_spotlight"}, {"surface": "metastatic", "start": 376, "end": 386, "uri": "http://dbpedia.org/resource/Metastasis", "source": "dbpedia_spotlight"}, {"surface": "radiation", "start": 457, "end": 466, "uri": "http://dbpedia.org/resource/Radiation_therapy", "source": "dbpedia_spotlight"}, {"surface": "metastasis", "start": 512, "end": 522, "uri": "http://dbpedia.org/resource/Metastasis", "source": "dbpedia_spotlight"}, {"surface": "Hormonal therapy", "start": 524, "end": 540, "uri": "http://dbpedia.org/resource/Hormone_therapy", "source": "dbpedia_spotlight"}, {"surface": "Cryotherapy", "start": 578, "end": 589, "uri": "http://dbpedia.org/resource/Cryosurgery", "source": "dbpedia_spotlight"}, {"surface": "tumor", "start": 619, "end": 624, "uri": "http://dbpedia.org/resource/Cancer", "source": "dbpedia_spotlight"}, {"surface": "hormonal therapy", "start": 627, "end": 643, "uri": "http://dbpedia.org/resource/Hormone_therapy", "source": "dbpedia_spotlight"}, {"surface": "chemotherapy", "start": 649, "end": 661, "uri": "http://dbpedia.org/resource/Chemotherapy", "source": "dbpedia_spotlight"}, {"surface": "cancer", "start": 712, "end": 718, "uri": "http://dbpedia.org/resource/Cancer", "source": "dbpedia_spotlight"}, {"surface": "Sipuleucel-T", "start": 731, "end": 743, "uri": "http://dbpedia.org/resource/Sipuleucel-T", "source": "dbpedia_spotlight"}, {"surface": "cancer vaccine", "start": 747, "end": 761, "uri": "http://dbpedia.org/resource/Cancer_vaccine", "source": "dbpedia_spotlight"}, {"surface": "metastatic", "start": 822, "end": 832, "uri": "http://dbpedia.org/resource/Metastasis", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 833, "end": 848, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "Hormonal", "start": 319, "end": 327, "uri": "https://calvoritmo.com/tfm/entity/85a1a9cb-8b0b-4a7e-abc0-b0e3a8cebcad", "source": "spacy"}, {"surface": "Hormonal", "start": 524, "end": 532, "uri": "https://calvoritmo.com/tfm/entity/dc9f7c05-52d3-46e3-9579-401e8cf85029", "source": "spacy"}, {"surface": "four-month", "start": 787, "end": 797, "uri": "https://calvoritmo.com/tfm/entity/62d0219d-adb6-4872-be8a-86621c42da18", "source": "spacy"}, {"surface": "19 May 2015", "start": 906, "end": 917, "uri": "https://calvoritmo.com/tfm/entity/f982c1c8-b536-4960-bd3a-698279c4fc62", "source": "spacy"}]}, {"text": "If radiation therapy fails, radical prostatectomy may be an option, though it is a technically challenging surgery. However, radiation therapy after surgical failure may have many complications. It is associated with a small increase in bladder and colon cancer. Radiotherapy and surgery appear to result in similar outcomes with respect to bowel, erectile and urinary function after five years.", "annotations": [{"surface": "after", "start": 143, "end": 148, "uri": "https://calvoritmo.com/tfm/entity/4e960aa1-e7f3-4d71-800d-df83b5846809", "source": "i"}, {"surface": "radiation therapy", "start": 3, "end": 20, "uri": "http://dbpedia.org/resource/Radiation_therapy", "source": "dbpedia_spotlight"}, {"surface": "prostatectomy", "start": 36, "end": 49, "uri": "http://dbpedia.org/resource/Prostatectomy", "source": "dbpedia_spotlight"}, {"surface": "radiation therapy", "start": 125, "end": 142, "uri": "http://dbpedia.org/resource/Radiation_therapy", "source": "dbpedia_spotlight"}, {"surface": "cancer", "start": 255, "end": 261, "uri": "http://dbpedia.org/resource/Cancer", "source": "dbpedia_spotlight"}, {"surface": "Radiotherapy", "start": 263, "end": 275, "uri": "http://dbpedia.org/resource/Radiation_therapy", "source": "dbpedia_spotlight"}, {"surface": "bowel", "start": 341, "end": 346, "uri": "http://dbpedia.org/resource/Fecal_incontinence", "source": "dbpedia_spotlight"}, {"surface": "five years", "start": 384, "end": 394, "uri": "https://calvoritmo.com/tfm/entity/5f5e62e6-1da4-49d4-bf86-a5812f5fee74", "source": "spacy"}]}], "subsections": [{"title": "Prognosis", "sectionItems": [{"text": "Many prostate cancers are not destined to be lethal, and most men will ultimately not die as a result of the disease. Mortality varies widely across geography and other elements. In the United States, five-year survival rates range from 29% (distant metastases) to 100% (local or regional tumors). In Japan, the fatality rate rose to 8.6/100,000 in 2000. In India in the 1990s, half of those diagnosed with local cancer died within 19 years. One study reported that African-Americans have 50\u201360 times more deaths than found in Shanghai, China. In Nigeria, 2% of men develop prostate cancer, and 64% of them are dead after 2 years. Most Nigerian men present with metastatic disease with a typical survival of 40 months.", "annotations": [{"surface": "India", "start": 358, "end": 363, "uri": "http://dbpedia.org/resource/India", "source": "a"}, {"surface": "Nigeria", "start": 547, "end": 554, "uri": "http://dbpedia.org/resource/Nigeria", "source": "a"}, {"surface": "geography", "start": 149, "end": 158, "uri": "http://dbpedia.org/resource/Geography", "source": "dbpedia_spotlight"}, {"surface": "United States", "start": 186, "end": 199, "uri": "http://dbpedia.org/resource/United_States", "source": "dbpedia_spotlight"}, {"surface": "five-year survival rates", "start": 201, "end": 225, "uri": "http://dbpedia.org/resource/Five-year_survival_rate", "source": "dbpedia_spotlight"}, {"surface": "metastases", "start": 250, "end": 260, "uri": "http://dbpedia.org/resource/Metastasis", "source": "dbpedia_spotlight"}, {"surface": "Japan", "start": 301, "end": 306, "uri": "http://dbpedia.org/resource/Japan", "source": "dbpedia_spotlight"}, {"surface": "India", "start": 358, "end": 363, "uri": "http://dbpedia.org/resource/India", "source": "dbpedia_spotlight"}, {"surface": "cancer", "start": 413, "end": 419, "uri": "http://dbpedia.org/resource/Cancer", "source": "dbpedia_spotlight"}, {"surface": "Shanghai", "start": 527, "end": 535, "uri": "http://dbpedia.org/resource/Shanghai", "source": "dbpedia_spotlight"}, {"surface": "China", "start": 537, "end": 542, "uri": "http://dbpedia.org/resource/China", "source": "dbpedia_spotlight"}, {"surface": "Nigeria", "start": 547, "end": 554, "uri": "http://dbpedia.org/resource/Nigeria", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 574, "end": 589, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "Nigerian", "start": 636, "end": 644, "uri": "http://dbpedia.org/resource/Nigeria", "source": "dbpedia_spotlight"}, {"surface": "metastatic", "start": 662, "end": 672, "uri": "http://dbpedia.org/resource/Metastasis", "source": "dbpedia_spotlight"}, {"surface": "the United States", "start": 182, "end": 199, "uri": "https://calvoritmo.com/tfm/entity/71889bd4-af59-4a42-b205-4aa421b1b9a1", "source": "spacy"}, {"surface": "five-year", "start": 201, "end": 210, "uri": "https://calvoritmo.com/tfm/entity/85745a75-e68f-4bad-bb1e-890a4024f4a9", "source": "spacy"}, {"surface": "29%", "start": 237, "end": 240, "uri": "https://calvoritmo.com/tfm/entity/bd3e5708-fb81-40c5-adda-1fd659154215", "source": "spacy"}, {"surface": "100%", "start": 265, "end": 269, "uri": "https://calvoritmo.com/tfm/entity/2a7f1757-9a98-4a2f-8fb3-188ced9e4a81", "source": "spacy"}, {"surface": "Japan", "start": 301, "end": 306, "uri": "https://calvoritmo.com/tfm/entity/ac72ad8b-c72f-4b84-8727-54276518b141", "source": "spacy"}, {"surface": "8.6/100,000", "start": 334, "end": 345, "uri": "https://calvoritmo.com/tfm/entity/19780a4c-418a-4d26-befb-12ed0fe5757e", "source": "spacy"}, {"surface": "2000", "start": 349, "end": 353, "uri": "https://calvoritmo.com/tfm/entity/06a8aea5-b054-4f59-885e-018acbd70bcd", "source": "spacy"}, {"surface": "India", "start": 358, "end": 363, "uri": "https://calvoritmo.com/tfm/entity/177b4f15-f3a8-464c-ba32-86a3536a177e", "source": "spacy"}, {"surface": "the 1990s", "start": 367, "end": 376, "uri": "https://calvoritmo.com/tfm/entity/604f83c2-ea25-4182-99f8-9589f60d6c02", "source": "spacy"}, {"surface": "half", "start": 378, "end": 382, "uri": "https://calvoritmo.com/tfm/entity/87aac84e-3b32-4eb3-ab43-af46ef3861f0", "source": "spacy"}, {"surface": "19 years", "start": 432, "end": 440, "uri": "https://calvoritmo.com/tfm/entity/5bf3406b-a1e5-4ca6-b438-59e5957b74aa", "source": "spacy"}, {"surface": "One", "start": 442, "end": 445, "uri": "https://calvoritmo.com/tfm/entity/3743fc50-7c29-4300-a0ab-41feaf12ab4b", "source": "spacy"}, {"surface": "African-Americans", "start": 466, "end": 483, "uri": "https://calvoritmo.com/tfm/entity/11410c53-3a12-4fcc-ad4a-3b2abfee925d", "source": "spacy"}, {"surface": "50\u201360", "start": 489, "end": 494, "uri": "https://calvoritmo.com/tfm/entity/7d8fe8a7-e53a-4147-9f49-7e51e9db2270", "source": "spacy"}, {"surface": "Shanghai", "start": 527, "end": 535, "uri": "https://calvoritmo.com/tfm/entity/8dd54e16-6ddd-4791-a030-d7dd2088d6b5", "source": "spacy"}, {"surface": "China", "start": 537, "end": 542, "uri": "https://calvoritmo.com/tfm/entity/a8ae457e-f91a-4ff0-98a5-16a8acc91d54", "source": "spacy"}, {"surface": "Nigeria", "start": 547, "end": 554, "uri": "https://calvoritmo.com/tfm/entity/fbb080a5-c0b1-4208-8645-e66585f9680c", "source": "spacy"}, {"surface": "2%", "start": 556, "end": 558, "uri": "https://calvoritmo.com/tfm/entity/3cb1b2d1-1521-4cf0-a4f0-f09f7b203491", "source": "spacy"}, {"surface": "64%", "start": 595, "end": 598, "uri": "https://calvoritmo.com/tfm/entity/64d018fc-5b57-47e7-ba61-468179c4f70b", "source": "spacy"}, {"surface": "2 years", "start": 622, "end": 629, "uri": "https://calvoritmo.com/tfm/entity/9b425ae2-fc13-4001-9faf-b8d9045b6052", "source": "spacy"}, {"surface": "Nigerian", "start": 636, "end": 644, "uri": "https://calvoritmo.com/tfm/entity/7b763a16-af01-44c6-ae3c-f1fdee49ba64", "source": "spacy"}, {"surface": "40 months", "start": 708, "end": 717, "uri": "https://calvoritmo.com/tfm/entity/3228e87d-a1e0-4a82-9b04-5fffd58b7c03", "source": "spacy"}]}, {"text": "In patients who undergo treatment, the most important clinical prognostic indicators of disease outcome are the stage, pretherapy PSA level, and Gleason score. The higher the grade and the stage, the poorer the prognosis. Nomograms can be used to calculate the estimated risk of the individual patient. The predictions are based on the experience of large groups of patients. A complicating factor is that the majority of patients have multiple independent tumor foci upon diagnosis, and these foci have independent genetic changes and molecular features. Because of this extensive inter-focal heterogeneity, it is a risk that the prognostication is set based on the wrong tumor focus.", "annotations": [{"surface": "Nomograms", "start": 222, "end": 231, "uri": "http://dbpedia.org/resource/Nomogram", "source": "a"}, {"surface": "PSA", "start": 130, "end": 133, "uri": "http://dbpedia.org/resource/Prostate-specific_antigen", "source": "dbpedia_spotlight"}, {"surface": "Gleason score", "start": 145, "end": 158, "uri": "http://dbpedia.org/resource/Gleason_grading_system", "source": "dbpedia_spotlight"}, {"surface": "prognosis", "start": 211, "end": 220, "uri": "http://dbpedia.org/resource/Prognosis", "source": "dbpedia_spotlight"}, {"surface": "tumor", "start": 457, "end": 462, "uri": "http://dbpedia.org/resource/Neoplasm", "source": "dbpedia_spotlight"}, {"surface": "tumor", "start": 673, "end": 678, "uri": "http://dbpedia.org/resource/Neoplasm", "source": "dbpedia_spotlight"}, {"surface": "PSA", "start": 130, "end": 133, "uri": "https://calvoritmo.com/tfm/entity/7dd06386-3545-4356-85fb-64d2e114f7b8", "source": "spacy"}, {"surface": "Gleason", "start": 145, "end": 152, "uri": "https://calvoritmo.com/tfm/entity/184dc6ea-be7c-4613-bc4c-7aba1a608389", "source": "spacy"}]}, {"text": "An important aspect of decision making on the value of treatment is how to balance prognosis from prostate cancer with other causes of mortality and the morbidity of treatment. The PREDICT Prostate algorithm (https://prostate.predict.nhs.uk) is a multivariable prognostic model that provides individualised cancer-specific and overall long-term survival estimates in early stage non-metastatic PCa patients. In addition to the use of routinely available preoperative clinical-pathological variables such as PSA, biopsy Gleason score (ISUP grade group), and clinical T-stage, the PREDICT Prostate tool also includes the impact of patient characteristics (age and comorbidity status) and radical treatment (radical prostatectomy or radiotherapy) on survival. The tool provides patients with estimated survival rates after treatment in the context of absolute mortality rate, which allows patients to make an informed decision as to the value of treatment and its potential side effects. Thurtle et al. performed an external validation of their previously published PREDICT Prostate model. The tool outperformed other widely used models and was proven to have high c-indices for all-cause and PCa-specific mortality, and the model calibration was good and remained accurate within the treatment subgroups. Recent work has also shown that it significantly alters clinician treatment recommendations and improves patients confidence in decision making and in their understanding of mortality risks from a new prostate cancer diagnosis  Predict Prostate is endorsed for use as a decision aid for prostate cancer by the UK National Institute for Health and Care Excellence ", "annotations": [{"surface": "prognosis", "start": 83, "end": 92, "uri": "http://dbpedia.org/resource/Prognosis", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 98, "end": 113, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "mortality", "start": 135, "end": 144, "uri": "http://dbpedia.org/resource/Mortality_rate", "source": "dbpedia_spotlight"}, {"surface": "morbidity", "start": 153, "end": 162, "uri": "http://dbpedia.org/resource/Disease", "source": "dbpedia_spotlight"}, {"surface": "algorithm", "start": 198, "end": 207, "uri": "http://dbpedia.org/resource/Algorithm", "source": "dbpedia_spotlight"}, {"surface": "PSA", "start": 507, "end": 510, "uri": "http://dbpedia.org/resource/Prostate-specific_antigen", "source": "dbpedia_spotlight"}, {"surface": "biopsy", "start": 512, "end": 518, "uri": "http://dbpedia.org/resource/Biopsy", "source": "dbpedia_spotlight"}, {"surface": "Gleason score", "start": 519, "end": 532, "uri": "http://dbpedia.org/resource/Gleason_grading_system", "source": "dbpedia_spotlight"}, {"surface": "ISUP", "start": 534, "end": 538, "uri": "http://dbpedia.org/resource/ISDN_User_Part", "source": "dbpedia_spotlight"}, {"surface": "T-stage", "start": 566, "end": 573, "uri": "http://dbpedia.org/resource/T-stage", "source": "dbpedia_spotlight"}, {"surface": "comorbidity", "start": 662, "end": 673, "uri": "http://dbpedia.org/resource/Comorbidity", "source": "dbpedia_spotlight"}, {"surface": "prostatectomy", "start": 713, "end": 726, "uri": "http://dbpedia.org/resource/Prostatectomy", "source": "dbpedia_spotlight"}, {"surface": "radiotherapy", "start": 730, "end": 742, "uri": "http://dbpedia.org/resource/Radiation_therapy", "source": "dbpedia_spotlight"}, {"surface": "mortality", "start": 857, "end": 866, "uri": "http://dbpedia.org/resource/Mortality_rate", "source": "dbpedia_spotlight"}, {"surface": "informed decision", "start": 906, "end": 923, "uri": "http://dbpedia.org/resource/Informed_Decision", "source": "dbpedia_spotlight"}, {"surface": "mortality", "start": 1203, "end": 1212, "uri": "http://dbpedia.org/resource/Mortality_rate", "source": "dbpedia_spotlight"}, {"surface": "mortality", "start": 1477, "end": 1486, "uri": "http://dbpedia.org/resource/Mortality_rate", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 1504, "end": 1519, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 1590, "end": 1605, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "UK", "start": 1613, "end": 1615, "uri": "http://dbpedia.org/resource/United_Kingdom", "source": "dbpedia_spotlight"}, {"surface": "PREDICT Prostate", "start": 181, "end": 197, "uri": "https://calvoritmo.com/tfm/entity/b1ea33b5-4693-4d16-ad82-e6ec5d9fb074", "source": "spacy"}, {"surface": "PSA", "start": 507, "end": 510, "uri": "https://calvoritmo.com/tfm/entity/9e280bcb-7817-4d2b-898c-64d2e23c680d", "source": "spacy"}, {"surface": "Gleason", "start": 519, "end": 526, "uri": "https://calvoritmo.com/tfm/entity/5324374e-47cf-4659-bcb4-3185a6f8f954", "source": "spacy"}, {"surface": "PREDICT Prostate", "start": 1063, "end": 1079, "uri": "https://calvoritmo.com/tfm/entity/d1ad0872-7ab6-42dc-977a-59ce4cc122f1", "source": "spacy"}, {"surface": "the UK National Institute for Health and Care Excellence", "start": 1609, "end": 1665, "uri": "https://calvoritmo.com/tfm/entity/349c87bd-8532-4f15-8534-b0f774343371", "source": "spacy"}]}, {"text": "Androgen ablation therapy causes remission in 80\u201390% of patients undergoing therapy, resulting in a median progression-free survival of 12 to 33 months. After remission, an androgen-independent phenotype typically emerges, wherein the median overall survival is 23\u201337 months from the time of initiation of androgen ablation therapy. How androgen-independence is established and how it re-establishes progression is unclear.", "annotations": [{"surface": "Androgen", "start": 0, "end": 8, "uri": "http://dbpedia.org/resource/Androgen", "source": "dbpedia_spotlight"}, {"surface": "ablation", "start": 9, "end": 17, "uri": "http://dbpedia.org/resource/Ablation", "source": "dbpedia_spotlight"}, {"surface": "progression-free survival", "start": 107, "end": 132, "uri": "http://dbpedia.org/resource/Progression-free_survival", "source": "dbpedia_spotlight"}, {"surface": "phenotype", "start": 194, "end": 203, "uri": "http://dbpedia.org/resource/Phenotype", "source": "dbpedia_spotlight"}, {"surface": "androgen", "start": 306, "end": 314, "uri": "http://dbpedia.org/resource/Androgen", "source": "dbpedia_spotlight"}, {"surface": "ablation", "start": 315, "end": 323, "uri": "http://dbpedia.org/resource/Ablation", "source": "dbpedia_spotlight"}, {"surface": "80\u201390%", "start": 46, "end": 52, "uri": "https://calvoritmo.com/tfm/entity/76522e50-93ec-4208-a9bd-46c0d27a6a4a", "source": "spacy"}, {"surface": "12 to 33 months", "start": 136, "end": 151, "uri": "https://calvoritmo.com/tfm/entity/abb5eb37-bfbd-4d77-bf26-19b68d710f9e", "source": "spacy"}, {"surface": "23\u201337 months", "start": 262, "end": 274, "uri": "https://calvoritmo.com/tfm/entity/5f183b74-6a17-4a1a-acda-bbb59cddcec0", "source": "spacy"}]}], "subsections": [{"title": "Classification systems", "sectionItems": [{"text": "Several tools are available to help predict outcomes, such as pathologic stage and recurrence after surgery or radiation therapy. Most combine stage, grade, and PSA level, and some include the number or percentage of biopsy cores positive, age, and/or other information.", "annotations": [{"surface": "radiation therapy", "start": 111, "end": 128, "uri": "http://dbpedia.org/resource/Radiation_therapy", "source": "dbpedia_spotlight"}, {"surface": "PSA", "start": 161, "end": 164, "uri": "http://dbpedia.org/resource/Prostate-specific_antigen", "source": "dbpedia_spotlight"}, {"surface": "biopsy", "start": 217, "end": 223, "uri": "http://dbpedia.org/resource/Biopsy", "source": "dbpedia_spotlight"}, {"surface": "PSA", "start": 161, "end": 164, "uri": "https://calvoritmo.com/tfm/entity/bece9b46-81af-448a-af81-6b752325a9a3", "source": "spacy"}]}, [{"text": "The D'Amico classification stratifies men by low, intermediate, or high risk based on stage, grade and PSA. It is used widely in clinical practice and research settings. The major downside to the three-level system is that it does not account for multiple adverse parameters (e.g., high Gleason score and high PSA) in stratifying patients.", "annotations": [{"surface": "and", "start": 301, "end": 304, "uri": "https://calvoritmo.com/tfm/entity/a931f6a1-cfe7-45e7-b6cc-aad192b4c814", "source": "i"}, {"surface": "PSA", "start": 103, "end": 106, "uri": "http://dbpedia.org/resource/Prostate-specific_antigen", "source": "dbpedia_spotlight"}, {"surface": "Gleason score", "start": 287, "end": 300, "uri": "http://dbpedia.org/resource/Gleason_grading_system", "source": "dbpedia_spotlight"}, {"surface": "PSA", "start": 310, "end": 313, "uri": "http://dbpedia.org/resource/Prostate-specific_antigen", "source": "dbpedia_spotlight"}, {"surface": "D'Amico", "start": 4, "end": 11, "uri": "https://calvoritmo.com/tfm/entity/6cbea0d3-5c6c-46a6-a175-48f79df62a69", "source": "spacy"}, {"surface": "PSA", "start": 103, "end": 106, "uri": "https://calvoritmo.com/tfm/entity/b0443806-46f9-4478-a772-5af821e16595", "source": "spacy"}, {"surface": "three", "start": 196, "end": 201, "uri": "https://calvoritmo.com/tfm/entity/17d488da-36a6-4aa4-aef9-6a863765c278", "source": "spacy"}, {"surface": "Gleason", "start": 287, "end": 294, "uri": "https://calvoritmo.com/tfm/entity/24ff9de0-0f4e-4c6d-9c76-26735469647a", "source": "spacy"}, {"surface": "PSA", "start": 310, "end": 313, "uri": "https://calvoritmo.com/tfm/entity/4458066b-74e1-4298-9550-e2b13a443bd1", "source": "spacy"}]}, {"text": "The Partin tables predict pathologic outcomes (margin status, extraprostatic extension, and seminal vesicle invasion) based on the same three variables and are published as lookup tables.", "annotations": [{"surface": "seminal vesicle", "start": 92, "end": 107, "uri": "http://dbpedia.org/resource/Seminal_vesicle", "source": "dbpedia_spotlight"}, {"surface": "Partin", "start": 4, "end": 10, "uri": "https://calvoritmo.com/tfm/entity/cd92fc63-b1c7-4554-ba84-0331d7b8d8fd", "source": "spacy"}, {"surface": "three", "start": 136, "end": 141, "uri": "https://calvoritmo.com/tfm/entity/9b1d3dd1-d078-4cad-a848-ddbf54f0bb14", "source": "spacy"}]}, {"text": "The Kattan nomograms predict recurrence after surgery and/or radiation therapy, based on data available at the time of diagnosis or after surgery. The Kattan score represents the likelihood of remaining free of disease at a given time interval following treatment.", "annotations": [{"surface": "nomograms", "start": 11, "end": 20, "uri": "http://dbpedia.org/resource/Nomogram", "source": "dbpedia_spotlight"}, {"surface": "radiation therapy", "start": 61, "end": 78, "uri": "http://dbpedia.org/resource/Radiation_therapy", "source": "dbpedia_spotlight"}, {"surface": "Kattan", "start": 4, "end": 10, "uri": "https://calvoritmo.com/tfm/entity/e04ba884-c6ab-47ac-84a4-a588398a67e9", "source": "spacy"}, {"surface": "Kattan", "start": 151, "end": 157, "uri": "https://calvoritmo.com/tfm/entity/914188d1-acb2-42c6-bc23-e2f495a6f98f", "source": "spacy"}]}, {"text": "The UCSF Cancer of the Prostate Risk Assessment (CAPRA) score predicts both pathologic status and recurrence after surgery. It offers accuracy comparable to the Kattan preoperative nomogram and can be calculated without tables or a calculator. Points are assigned based on PSA, grade, stage, age, and percentage of cores positive; the sum yields a 0\u201310 score, with every two points representing roughly a doubling of risk of recurrence. The CAPRA score was derived from community-based data in the CaPSURE database. It has been validated among over 10,000 prostatectomy patients, including patients from CaPSURE; the SEARCH registry, representing data from several Veterans Health Administration and military medical centers; a multi-institutional cohort in Germany; and the prostatectomy cohort at Johns Hopkins University. More recently, it has been shown to predict metastasis and mortality following prostatectomy, radiation therapy, watchful waiting, or androgen deprivation therapy.", "annotations": [{"surface": "Veterans Health Administration", "start": 665, "end": 695, "uri": "http://dbpedia.org/resource/Veterans_Health_Administration", "source": "a"}, {"surface": "UCSF", "start": 4, "end": 8, "uri": "http://dbpedia.org/resource/UCSF_Medical_Center", "source": "dbpedia_spotlight"}, {"surface": "nomogram", "start": 181, "end": 189, "uri": "http://dbpedia.org/resource/Nomogram", "source": "dbpedia_spotlight"}, {"surface": "calculator", "start": 232, "end": 242, "uri": "http://dbpedia.org/resource/Calculator", "source": "dbpedia_spotlight"}, {"surface": "PSA", "start": 273, "end": 276, "uri": "http://dbpedia.org/resource/Prostate-specific_antigen", "source": "dbpedia_spotlight"}, {"surface": "database", "start": 506, "end": 514, "uri": "http://dbpedia.org/resource/Database", "source": "dbpedia_spotlight"}, {"surface": "prostatectomy", "start": 556, "end": 569, "uri": "http://dbpedia.org/resource/Prostatectomy", "source": "dbpedia_spotlight"}, {"surface": "Veterans Health Administration", "start": 665, "end": 695, "uri": "http://dbpedia.org/resource/Veterans_Health_Administration", "source": "dbpedia_spotlight"}, {"surface": "Germany", "start": 758, "end": 765, "uri": "http://dbpedia.org/resource/Nazi_Germany", "source": "dbpedia_spotlight"}, {"surface": "prostatectomy", "start": 775, "end": 788, "uri": "http://dbpedia.org/resource/Prostatectomy", "source": "dbpedia_spotlight"}, {"surface": "metastasis", "start": 869, "end": 879, "uri": "http://dbpedia.org/resource/Metastasis", "source": "dbpedia_spotlight"}, {"surface": "mortality", "start": 884, "end": 893, "uri": "http://dbpedia.org/resource/Mortality_rate", "source": "dbpedia_spotlight"}, {"surface": "prostatectomy", "start": 904, "end": 917, "uri": "http://dbpedia.org/resource/Prostatectomy", "source": "dbpedia_spotlight"}, {"surface": "radiation therapy", "start": 919, "end": 936, "uri": "http://dbpedia.org/resource/Radiation_therapy", "source": "dbpedia_spotlight"}, {"surface": "watchful waiting", "start": 938, "end": 954, "uri": "http://dbpedia.org/resource/Watchful_waiting", "source": "dbpedia_spotlight"}, {"surface": "androgen", "start": 959, "end": 967, "uri": "http://dbpedia.org/resource/Androgen", "source": "dbpedia_spotlight"}, {"surface": "the Prostate Risk Assessment", "start": 19, "end": 47, "uri": "https://calvoritmo.com/tfm/entity/11bd4e5e-f31c-44ac-b358-641599d0fa75", "source": "spacy"}, {"surface": "Kattan", "start": 161, "end": 167, "uri": "https://calvoritmo.com/tfm/entity/194a8337-d9fa-47e4-8780-c852a8d080ab", "source": "spacy"}, {"surface": "PSA", "start": 273, "end": 276, "uri": "https://calvoritmo.com/tfm/entity/9cc6c1bc-dcc1-4fd8-8fd7-e8b23a7f1aa8", "source": "spacy"}, {"surface": "0\u201310", "start": 348, "end": 352, "uri": "https://calvoritmo.com/tfm/entity/b507d0cf-15a9-4131-b481-2ba0d2d0ec1a", "source": "spacy"}, {"surface": "two", "start": 371, "end": 374, "uri": "https://calvoritmo.com/tfm/entity/d1eecd94-c31b-4cc3-b087-3ae10a48c8ee", "source": "spacy"}, {"surface": "over 10,000", "start": 544, "end": 555, "uri": "https://calvoritmo.com/tfm/entity/2cbe252f-862b-4561-bea5-9c223781a839", "source": "spacy"}, {"surface": "SEARCH", "start": 617, "end": 623, "uri": "https://calvoritmo.com/tfm/entity/6bef352c-1544-44fb-bf79-77de2f800c42", "source": "spacy"}, {"surface": "Veterans Health Administration", "start": 665, "end": 695, "uri": "https://calvoritmo.com/tfm/entity/82399b91-7128-4e41-aea8-5f034d047933", "source": "spacy"}, {"surface": "Germany", "start": 758, "end": 765, "uri": "https://calvoritmo.com/tfm/entity/3fc84111-badb-4605-8563-f394e1848262", "source": "spacy"}, {"surface": "Johns Hopkins University", "start": 799, "end": 823, "uri": "https://calvoritmo.com/tfm/entity/2d0ad224-dcf0-4fc0-bab6-fed526683370", "source": "spacy"}]}, {"text": "The UK National Institute for Health and Care Excellence guidelines recommends use of the Cambridge Prognostic Groups (CPG) 5-tier model when determining treatment options. The rationale for the change related to recent evidence, which suggests that 5-tier risk stratification model was better at predicting prostate cancer specific mortality than older 3-tier models  The CPG model has been tested and validated in studies including >80,000 men  The NICE CPG model and treatment recommendations can be viewed at the NICE guideline website.", "annotations": [{"surface": "UK", "start": 4, "end": 6, "uri": "http://dbpedia.org/resource/United_Kingdom", "source": "dbpedia_spotlight"}, {"surface": "Cambridge", "start": 90, "end": 99, "uri": "http://dbpedia.org/resource/University_of_Cambridge", "source": "dbpedia_spotlight"}, {"surface": "prostate cancer", "start": 308, "end": 323, "uri": "http://dbpedia.org/resource/Prostate_cancer", "source": "dbpedia_spotlight"}, {"surface": "mortality", "start": 333, "end": 342, "uri": "http://dbpedia.org/resource/Mortality_rate", "source": "dbpedia_spotlight"}, {"surface": "The NICE", "start": 447, "end": 455, "uri": "http://dbpedia.org/resource/The_Nice", "source": "dbpedia_spotlight"}, {"surface": "NICE", "start": 517, "end": 521, "uri": "http://dbpedia.org/resource/National_Institute_for_Health_and_Care_Excellence", "source": "dbpedia_spotlight"}, {"surface": "The UK National Institute for Health and Care Excellence", "start": 0, "end": 56, "uri": "https://calvoritmo.com/tfm/entity/22fd4188-47f9-485a-9ef7-f2c25312fa94", "source": "spacy"}, {"surface": "CPG", "start": 119, "end": 122, "uri": "https://calvoritmo.com/tfm/entity/d471bac0-9ba4-49e1-b1f5-29dfef93156b", "source": "spacy"}, {"surface": "5", "start": 124, "end": 125, "uri": "https://calvoritmo.com/tfm/entity/614acb2e-a7f6-4d90-a50f-2440d778511d", "source": "spacy"}, {"surface": "5", "start": 250, "end": 251, "uri": "https://calvoritmo.com/tfm/entity/7e6c4182-0440-4414-978e-1417b9ead67f", "source": "spacy"}, {"surface": "3", "start": 354, "end": 355, "uri": "https://calvoritmo.com/tfm/entity/16f8e868-db1d-41b2-8d57-3dcb76d5d6f7", "source": "spacy"}, {"surface": "CPG", "start": 373, "end": 376, "uri": "https://calvoritmo.com/tfm/entity/7e89f7d5-13d5-490a-baf9-507120956396", "source": "spacy"}, {"surface": "NICE", "start": 451, "end": 455, "uri": "https://calvoritmo.com/tfm/entity/96c15062-2e96-4dba-8ead-3b182708355a", "source": "spacy"}, {"surface": "NICE", "start": 517, "end": 521, "uri": "https://calvoritmo.com/tfm/entity/5bc4e032-f1f2-40b8-bc85-017b861cd4ea", "source": "spacy"}]}]], "subsections": []}]}]}]}]}]}]}]}]}]}]}]}}